New Vaccine-Drug combo targets Hard-to-Treat breast cancer
NCT ID NCT06691035
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests whether combining a special immune-boosting vaccine (DC1) with the drug elacestrant is safe and doable for people with a common type of advanced breast cancer (HR+ HER2-). About 18 participants will receive the treatment for 8 weeks. The goal is to see if the body can better fight the cancer, but this is not a cure—it aims to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER, METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
- Heating up tumors: could thermal therapy boost immune attack on breast cancer?
- Could a diabetes drug slow breast cancer growth?
- Mapping the hidden toll: how breast cancer brain metastases affect daily life
- Immune-Boosting cocktail aims to tackle Hard-to-Treat breast cancer
- Old arthritis drug takes on tough cancers in early trial